PRINCETON, NJ--(MARKET WIRE)--Jun 6, 2007 -- Barrier Therapeutics, Inc. (NasdaqGM:BTRX - News), a pharmaceutical company that develops and markets dermatology products, today announced that it has launched a new 50g-size tube of its Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment. Vusion Ointment is the only prescription product approved in the U.S. for the treatment of diaper dermatitis, also known as diaper rash, complicated with a documented fungal infection caused by yeast known as Candida.
